18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: Comparison of early to delayed imaging with and without liver activity normalization

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 379-385

  Chirindel, Alin ^a,b,c   Chaudhry, Muhammad ^a,d   Blakeley, Jaishri O ^a   Wahl, Richard ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DHAHRAN HEALTH CENTER   (Saudi Arabia)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDGPET CT; Early and delayed; NF1; Quantitative and qualitative

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER FUNCTION; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; NEUROFIBROMATOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYMPTOM; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LIVER; MIDDLE AGED; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS TYPE 1; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84928116726     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.142372     Document Type: Article

References (26)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89:1-6.
2. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151:33-40.
3. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81-88.
4. Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol. 2014;116:307-313.
5. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314.
6. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. Cancer Res. 2002;62:1573-1577.
7. Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR. 2010;194:1568-1574.
8. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet. 1999;89:23-30.
9. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol. 2010;136:1869-1880.
10. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009;21:345-351.
11. 18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19:390-394.
12. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type I. AJR. 2007;189:928-935.
13. 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS ONE. 2014;9:e85954.
14. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36:751-757.
15. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014;24:405-412.
16. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.
17. 18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol. 2008;87:165-171.
18. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery. 2009;65:A160-A170.
19. Moharir M, London K, Howman-Giles R, North K. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2010;37:1309-1317.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.
21. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68:353-357.
22. Cardona S, Schwarzbach M, Hinz U, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol. 2003;29:536-541.
23. 18F]-fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012;108:469-475.
24. Brenner W, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging. 2006;33:428-432.
25. Bensaid B, Giammarile F, Mognetti T, et al. Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1. Ann Dermatol Venereol. 2007;134:735-741.
26. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116:451-458.